Evidence map›Paper›PMID 31473221›Full record

ReviewBrain research2019

The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era.

Vanessa Chilunda, Tina M Calderon, Pablo Martinez-Aguado, Joan W Berman

Open access · greenAbstract readReview
In one paragraph

Review in Brain research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Neurocognitive function and its influencing factors in people living with HIV/AIDS.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Vanessa ChilundaDepartment of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, USA.
Tina M CalderonDepartment of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, USA.
Pablo Martinez-AguadoDepartment of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, USA.
Joan W BermanDepartment of Pathology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, USA; Department of Microbiology and Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, USA. Electronic address: joan.berman@einstein.yu.edu.
Albert Einstein College of Medicine · US

Funding

Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vinayaka R. Prasad · 2017 to 2026
$28.3M
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuseR01DA041931 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Joan Weinberger Berman, JENNIFER L KELSCHENBACH · 2017 to 2026
$7.4M
Mechanisms of opioid- mediated HIV neuropathogenesisR01DA048609 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BERMAN, JOAN WEINBERGER, GOLDSTEIN, HARRIS · 2019 to 2023
$4.2M
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruptionR01DA044584 · NIDA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BERMAN, JOAN WEINBERGER, GOLDSTEIN, HARRIS · 2017 to 2021
$4.0M
Monocyte CNS HIV entry & neurodegeneration: Translational studies in the CART eraR01MH112391 · NIMH · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BERMAN, JOAN WEINBERGER, MORGELLO, SUSAN · 2017 to 2021
$3.7M
NIAID NIH HHS P30 AI124414NIDA NIH HHS R01 DA041931NIDA NIH HHS R01 DA044584NIDA NIH HHS R01 DA048609NIMH NIH HHS R01 MH112391
6 · The paper itself

Abstract

Approximately 37 million people worldwide are infected with human immunodeficiency virus (HIV). One highly significant complication of HIV infection is the development of HIV-associated neurocognitive disorders (HAND) in 15-55% of people living with HIV (PLWH), that persists even in the antiretroviral therapy (ART) era. The entry of HIV into the central nervous system (CNS) occurs within 4-8 days after peripheral infection. This establishes viral reservoirs that may persist even in the presence of ART. Once in the CNS, HIV infects resident macrophages, microglia, and at low levels, astrocytes. In response to chronic infection and cell activation within the CNS, viral proteins, inflammatory mediators, and host and viral neurotoxic factors produced over extended periods of time result in neuronal injury and loss, cognitive deficits and HAND. Substance abuse is a common comorbidity in PLWH and has been shown to increase neuroinflammation and cognitive disorders. Additionally, it has been associated with poor ART adherence, and increased viral load in the cerebrospinal fluid (CSF), that may also contribute to increased neuroinflammation and neuronal injury. Studies have examined mechanisms that contribute to neuroinflammation and neuronal damage in PLWH, and how substances of abuse exacerbate these effects. This review will focus on how substances of abuse, with an emphasis on methamphetamine (meth), cocaine, and opioids, impact blood brain barrier (BBB) integrity and transmigration of HIV-infected and uninfected monocytes across the BBB, as well as their effects on monocytes/macrophages, microglia, and astrocytes within the CNS. We will also address how these substances of abuse may contribute to HIV-mediated neuropathogenesis in the context of suppressive ART. Additionally, we will review the effects of extracellular dopamine, a neurotransmitter that is increased in the CNS by substances of abuse, on HIV neuropathogenesis and how this may contribute to neuroinflammation, neuronal insult, and HAND in PLWH with active substance use. Lastly, we will discuss some potential therapies to limit CNS inflammation and damage in HIV-infected substance abusers.

Indexed as

AIDS Dementia ComplexAstrocytesBlood-Brain BarrierBrainCentral Nervous System DiseasesHIV InfectionsHumansMacrophagesMicrogliaMonocytesSubstance-Related DisordersViral LoadAntiretroviral therapyCNSHIV associated neurocognitive disordersMacrophagesMonocytesSubstances of abuse

Identifiers

PMID31473221
PMCPMC6889827
OpenAlexW2970860254

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.